Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)

NCT06048133 is registered in ClinicalTrials.gov with Nataliya Uboha as lead sponsor.

NCT NCT06048133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06048133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)
Lead sponsor
Nataliya Uboha
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 8, 2024
Completion date
July 31, 2027
Enrollment
33 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, biliary tract carcinoma, cholangiocarcinoma